epidermal-growth-factor and Keratitis--Herpetic

epidermal-growth-factor has been researched along with Keratitis--Herpetic* in 2 studies

Trials

1 trial(s) available for epidermal-growth-factor and Keratitis--Herpetic

ArticleYear
Epidermal growth factor in the topical treatment of herpetic corneal ulcers.
    Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 1994, Volume: 208, Issue:1

    The tolerability and efficacy of epidermal growth factor (EGF) in the topical treatment of herpetic corneal ulcers in addition to topical acyclovir have been evaluated in a double-blind, placebo-controlled, randomized study in two groups of patients. The time required for complete reepithelialization of the cornea was recorded, and the data obtained were analyzed statistically. In the EGF group, the reepithelialization was significantly faster than in the control group. Tolerability of EGF was always excellent. These results indicate that EGF is safe and effective in reducing the healing time of herpetic corneal ulcers.

    Topics: Acyclovir; Administration, Topical; Adult; Aged; Corneal Ulcer; Double-Blind Method; Epidermal Growth Factor; Female; Humans; Keratitis, Herpetic; Male; Middle Aged; Ophthalmic Solutions

1994

Other Studies

1 other study(ies) available for epidermal-growth-factor and Keratitis--Herpetic

ArticleYear
Aggravation of herpetic stromal keratitis after murine epidermal grown factor topical application.
    Cornea, 1994, Volume: 13, Issue:2

    We evaluated the epithelializing-promoting effect of a concentration of 0.005 mg/ml murine epidermal growth factor (mEGF), topically administered four times daily, on the herpes simplex virus 1 (HSV-1) corneal ulcers of the rabbit eye. The severity of the herpetic lesions was evaluated clinically, after the time course of the severity of epithelial keratitis, conjunctivitis, iritis, and stromal disease, for 14 days. A histological assessment was performed in the middle and at the end of the follow-up. The stromal keratitis of the mEGF-treated group was significantly more severe than the keratitis exhibited by the placebo-treated rabbits (Y = X3 X2*X4; p = 0.0001). There were no significant differences in the degree of conjunctivitis, epithelial keratitis, iritis, and virus shedding between these groups. No evidence of a toxic effect of mEGF or placebo was found in the mock infected rabbit eyes. More studies, using different herpes virus strains and a broad range of murine and human EGF concentrations, are mandatory to ascertain the general significance of these results. Meanwhile, caution is recommended when using mEGF in the presence of an occult or manifest herpetic eye disease.

    Topics: Administration, Topical; Animals; Corneal Stroma; Disease Models, Animal; Epidermal Growth Factor; Herpesvirus 1, Human; Keratitis, Herpetic; Mice; Rabbits; Random Allocation; Vero Cells; Virus Shedding

1994